Development of antineoplastic gene therapies is impaired by a paucity of transcription control elements with efficient, cancer cellspecific activity. We investigated the utility of promoter (AChP) and 5 0 -distal enhancer (ACE66) elements from the platelet-derived growth factor-A (PDGF-A) gene, which are hyperactive in many human cancers. Efficacy of these elements was tested in multiple tumor cell lines, both in cell culture and as tumor explants in athymic nude mice. Plasmid and viral vectors were constructed with the AChP promoter alone or in fusion with three copies of the ACE66 enhancer for expression of the prototype suicide gene, thymidine kinase (TK). ACE/AChP and AChP cassettes elicited ganciclovir (GCV)-induced cytotoxicity in multiple tumor cell lines. The ACE enhancer element also exhibited synergism with placental and liver-specific promoter elements. An adenovirus containing the AChP-TK cassette produced striking increases in GCV sensitivity in cultured tumor cell lines, as well as GCV-induced regression of U87 MG glioblastoma explants in vivo. TK expression was distributed throughout tumors receiving the therapeutic virus, whereas TdT-mediated dUTP nick end labeling (TUNEL) analysis revealed numerous regions undergoing apoptosis. Vascularization and reticulin fiber networks were less pronounced in virus-GCV-treated tumors, suggesting that both primary and stromal cell types may have been targeted. These studies provide proof-of-principle for utility of the PDGF-A promoter and ACE66 enhancer in antineoplastic gene therapy for a diverse group of human cancers.
Introduction
Current approaches to antineoplastic gene therapy have been hampered by suboptimal delivery of therapeutic genes to tumor tissues, as well as inadequate strength, specificity and duration of expression. A potential source of such elements is growth factor genes, which are often overexpressed in human cancers. The genes encoding platelet-derived growth factor (PDGF) ligands represent promising candidates in light of their marked overexpression in a multitude of human cancer cell types, [1] [2] [3] and the critical oncogenic stimuli they generate via autocrine and paracrine growth loop activity. [3] [4] [5] The PDGF family of ligands consist of four subunits, PDGF-A, PDGF-B, PDGF-C and PDGF-D, which dimerize via disulfide linkages to form the homodimers PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD and the heterodimer PDGF-AB. These ligands bind and activate with varying specificities to the PDGF receptors a and b, which are prototypical receptor tyrosine kinases. 6, 7 Basal transcription of the PDGF-A gene has been attributed to the highly GC-rich promoter region, located between À120 and À40 relative to the transcription start site. 8, 9 Activity is mediated through binding of Sp/ Kruppel-like factor proteins to at least five consensus binding motifs, whereas the promoter region also contains binding sites for the single-stranded DNA-binding activator Pura, 10 as well as the transcriptional repressors WT-1, 11, 12 GC factor 2 13 and nuclear factor I-X. 14 However, specific mechanisms underlying hyperactivation of the PDGF-A promoter (AChP) in human malignancy remain to be fully elucidated. Of additional relevance is a complex enhanceosome located within the 5 0 -distal region of the PDGF-A gene (À7294 to À6787), which is highly activated in a number of transformed cell lines. 15 This region contains a potent 66 bp enhancer (ACE66) which contains four tandemly arranged half-sites for binding of nuclear receptors, a ternary complex factor motif and overlapping response elements for vitamin D 16 and retinoic acid. 17 A high degree of transcriptional synergism is obtained with three directly repeated copies of the ACE66 element, ranging from 30-fold enhancement in HepG2 (hepatoma) and U2-OS (osteosarcoma) cells to 200-fold in JEG-3 and other choriocarcinoma lines. Constitutive activation of the ACE66 element in choriocarcinoma cells is mediated by ligand-independent recruitment of the vitamin D receptor and AP-1-like factors, as well as signaling via the jun-kinase cascade. 18 Activity of the ACE66 element is negligible in nontransformed cell types evaluated to date, suggesting utility not only as a source of strong transcriptional activity in certain cancers, but a high degree of cancer cell selectivity as well.
In this report, we show that plasmid and adenoviral vectors driving thymidine kinase (TK) expression under control of the AChP confer a high degree of chemosensitization to the prodrug ganciclovir (GCV). This effect was observed across a diverse panel of human tumor cell lines in culture, as well as in vivo in the context of subcutaneous tumor explants of the glioblastoma cell line U87 MG. An additional boost to TK expression and GCV-induced cytopathogenicity was provided in a number of cancer cell types by the ACE66 element. These studies provide proofof-principle that transcriptional elements from the PDGF-A gene can provide efficacious and cancer-specific delivery of therapeutic gene expression. They also suggest that genes encoding other growth factors and their receptors may represent a reservoir of other elements with potential applicability to cancer gene therapy.
Materials and methods
Cell lines and culture conditions JEG-3, JAR, U2-OS, Saos-2, U87, Hs68 and HepG2 cells were obtained from the American Type Culture Collection. The following cell lines were generous gifts: FK121 (M Herlyn, Wistar Institute), H441 (J Whitsett, University of Cincinnati), HEK-293 (S Kraner, University of Kentucky) and 293FT (L Hersh, University of Kentucky). JEG-3, HepG2, Saos-2, Hs68, HEK-293 and 293 FT cells were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum (FBS), 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. FK121 cells were cultured in keratinocyte serum-free medium supplemented with 20 mg ml À1 bovine pituitary extract and 1 ng ml À1 of epidermal growth factor. JAR and H441 cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. All culture media and media additions were obtained from GibcoBRL (Grand Island, NY).
Plasmid constructs
For construction of TK expression plasmids, aB2 kb TK cDNA fragment was excised from pHSV-106 19 with BamHI and inserted into the BgII/BamHI site of pBSKII À to generate the parent vector, pBSKII-tk. The AChP (À261 to þ 8) was excised as a 280 bp XhoIHindIII fragment from pGL3-AChP 15 and inserted into the XhoI-HindIII site of pBSKII-tk, yielding pBSKIIAChPtk. To place the TK gene under transcriptional control of three directly repeated copies of the ACE66 element in fusion with the AChP, a 500 bp SstI-HindIII fragment was excised from pGL3-3XACE/AChP, 15 and inserted into the blunt-ended HindIII site of pBSKII-tk to generate pBSKII-3XACE/AChPtk.
To create vectors containing the human glycoprotein hormone a subunit promoter (hFHaP), a 1.5 kb XhoIHindIII fragment was excised from pHa (-1500)Luc 20 (a gift from R. Keri, Case Western Reserve University) and inserted into the corresponding site of pGL3-Basic (Promega Corporation, Madison, WI) to generate pGL3-hGPHaPluc. For placement of three tandem copies of the ACE66 element upstream of the hGPHaP promoter, a 350 bp fragment harboring the multimer was isolated by XmaI digestion of pGL3-3XACE/AChP and inserted into the XmaI site of pBSKII À to generate pBSKII-3XACE. The ACE66 trimer was isolated as a 350 bp KpnI-SstI fragment from pBS-3XACE and inserted into pGL3-hGPHaPluc to generate pGL3-ACE/hGPHaPluc.
For fusion of the AFP promoter (ha-fpP) and ACE66 enhancer, a parent vector was first prepared by excision of a 296 bp BamHI-HindIII fragment containing the AFP promoter from pA-AFP-LacZ, 21 followed by insertion into the BglII-HindIII site of pGL3-Basic (Promega Corporation) to generate pGL3-AFPluc. A 350 bp KpnI-SstI fragment containing the ACE66 trimer was excised from pBS-3XACE and cloned into pGL3-AFPluc to yield pGL3-3XACE/AFPluc. For constructs containing the H19 enhancer (H19E1) in combination with ACE66 and AChP, a 290 bp EcoRI fragment containing the H19E1 enhancer was transferred from pmH19E1-APd44-LacZ 22 to pBSKII À , generating pBS-H19E1. A 290 bp KpnI-SstI fragment containing the H19E1 element was isolated from pBS-H19E1 and inserted into pGL3-AChP-Luc to generate pGL3-H19E1/AChPluc. The same KpnI-SstI fragment was inserted into pGL3-3XACE/ AChPluc to generate pGL3-H19E1/3XACE/AChP-luc.
Generation of adenoviral vectors
To obtain shuttle plasmids for recombination of transcriptional units into the replication-incompetent adenovirus Ad5, TK cDNA and 3XACE/AChPtk cassettes were first isolated as BamHI/ClaI fragments from the respective pBSKII À -derived vectors described above. These were inserted into the corresponding sites of pAdLink (courtesy of S. Kraner, University of Kentucky), yielding pAdLink-tk and pAdLink-3XACE/ AChPtk, respectively. A pAdLink vector containing the AChPtk cassette was obtained by a partial treatment of pAd-3XACE/AChPtk with KpnI and BamHI. The resulting 2.2 kb fragment was reinserted into the corresponding site of pAdLink to generate pAdLink-AChPtk. For recombination, HEK-293 cells (2 Â 10 6 ) constitutively expressing the adenoviral E1 gene were seeded into 60 mm dishes. Cells were transfected 24 h later with 3.2 mg of ClaI-digested Ad5 viral DNA plus 4.8 mg of one of the respective NheI-digested pAdLink plasmids (pAdLink-tk, pAdLink-AChPtk and pAdLink-3XACE/ AChPtk). Viral plaques were isolated and propagated by successive passaging and enrichment in HEK-293 cells. DNA from viral plaques was screened for TK sequence by dot-blot analysis using a 300 bp radiolabeled probe derived from the TK cDNA. The DNA probe was generated by PCR with internal primers (upstream primer: 5 0 -GCGAACATCTACACCACACAACACCG-3 0 ; downstream primer: 5 0 -GTAGCACAGGAGGGCGGCGAT-3 0 ) and pBSKII-tk as template, followed by radiolabeling by fill-in with Klenow fragment of DNA polymerase I and 32 P-dCTP (3000 Ci mmol
À1
; Perkin-Elmer, Boston, MA). Correct recombination of DNA fragments into adenovirus was verified by Southern blot with the 32 P-labeled TK probe, followed by another round of plaque purification and Southern blotting. Viral DNAs were assayed for potential contamination by wild-type adenovirus using PCR as described. Adenoviruses were amplified in HEK-293 cells, purified by CsCl density gradient centrifugation, 23 and eluted in buffer containing 50 mM Hepes (pH 7.2), 0.9% NaCl, 0.5 mM MgCl 2 , 0,5 mM CaCl 2 and 0.5% bovine serum albumin. Purified recombinant viruses were reassayed for wildtype Ad5 by PCR. Ad5-CMV/LacZ/IRESgfp has been described previously. 24 Adenoviral titers were determined by using Adeno-X Rapid Titer Kit (Clontech Laboratories, Mountain View, CA), and were as follows: Ad5-ACE/AchPtk, 3.6 Â 10 10 i.f.u. ml
, Ad5-AchPtk, 2 Â 10 11 i.f.u. ml À1 , and Ad5-CMV/LacZ/IRESgfp was 4.9 Â 10 11 i.f.u. ml À1 . Adenovirus stocks were stored in 5% glycerol buffer at À80 1C.
Immunoblot analysis of TK expression
For analysis of TK expression, JEG-3, HepG2 and H441 cells were seeded at 10 6 cells per 100 mm dish and transfected with 10 mg of TK expression plasmids. For analysis of TK expression in adenovirally infected cells, JEG-3 cells were seeded as above and infected at a multiplicity of infection (MOI) of 200. At 48 h after transfection or adenoviral infection, cells were detached with Dulbecco's phosphate-buffered saline (DPBSa) containing 0.5 mM EDTA, pelleted by centrifugation at 1000 g for 5 min, and disrupted in lysis buffer (50 mM Tris HCl, 150 mM NaCl, 1% NP-40, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, pH 8.0) containing protease inhibitors aprotinin, leupeptin and antipain at 10 mg ml
À1
. Protein concentrations were determined by Bradford assay (Bio-Rad, Richmond, CA) and measuring absorbance at 620 nm (Anthos Reader 2001; Anthos Labtec, Cambridge, UK). Cell extract (50 mg) was subjected to SDS-polyacrylamide gel electrophoresis (12% gels) under reducing conditions, followed by semi-dry blotting (Bio-Rad, Hercules, CA) to nitrocellulose filters (Trans-Blot Transfer Medium, 0.45 ı`m; Bio-Rad). TK protein was detected by incubation with polyclonal rabbit anti-TK (provided by W. Summers, Yale) at a 1:500 dilution for 1 h at 22 1C followed by incubation with goat anti-rabbit IgG-horseradish peroxidase conjugate (1:10 000; Santa Cruz Biotechnology, Santa Cruz, CA), and the Supersignal West Pico chemiluminescence kit (Pierce, Rockford, IL). , with replacement of GCV-containing medium every 3 days. Cell viability was determined on day 8 of GCV treatment, using the Cell Titer 96 AQ ueous Non-Radioactive Cell Proliferation Assay (Promega Corporation). Absorbance at 490 nm was recorded using a HTS 7000 Plus BioAssay Reader (Perkin-Elmer). Percent survival (mean þ s.e.) was calculated as the ratio of absorbance at 490 nm in GCV-treated versus nontreated cells.
For adenoviral infection experiments, JEG-3, JAR, HepG2, U2-OS, U87, Saos-2, Hs68 cells and 4000 FK121 cells were seeded into 24-well plates at 10 4 cells per well. Cells were infected with adenoviral vectors at an MOI of 200 i.f.u. per cell. After 12 h, virus-containing media was replaced with fresh complete media containing GCV, with cell viability assays conducted at day 6.
Tumor growth in athymic nude mice Animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Kentucky. Female athymic nude mice at 7 weeks of age (Harlan, Indianapolis, IN) were maintained in quarantine for 1 week before study. Mice were injected subcutaneously within their left flank region with 10 7 U87 MG cells suspended in 100 ml of DPBSa. After primary tumors reached a volume of 40-45 mm 3 (within 7-10 days), animals were randomly assigned to treatment groups. Adenoviruses were delivered intratumorally on two consecutive days at a 10 9 virus particles per 100 ml injection. At 24 h after the second adenovirus injection, GCV was administered via intraperitoneal injection once daily for 14 days at a dose of 75 mg kg À1 body weight. At 24 h after the final dose of GCV, mice were killed by CO 2 asphyxiation followed by cervical dislocation. Tumors were excised, bisected with a scalpel and fixed for 16 h in 4% paraformaldehyde, followed by dehydration with stepwise increasing concentrations of ethanol, paraffinembedding and sectioning (5 mm).
Analysis of tumor tissue sections
Formaldehyde-fixed tumor sections were deparaffinized by four 10 min washes in 100% xylene, followed by rehydration with 1 min washes in decreasing concentrations of ethanol (100, 95, 95, 80, 70 and 0%). Apoptotic cells were identified by TdT-mediated dUTP nick end labeling (TUNEL) assay using an In situ Death Detection Kit, Fluorescein (Roche Diagnostics Corporation). For immunohistochemical analysis of TK protein expression, sections were incubated in 10% goat serum in phosphatebuffered saline (PBS) and blocked with excess streptavidin and biotin as described in the instructions of the ABC immunostaining kit (Vector Laboratories, Burlingame, CA). Sections were then treated with 1:150 of primary rabbit anti-HSV1-TK antibody, followed by 5 mg ml À1 of secondary biotinylated goat anti-rabbit IgG and 10 mg ml À1 of tertiary streptavidin-fluorescein conjugate. Sections were washed three times with DPBSa between all antibody and conjugate incubation steps. All dilutions were made in 1.5% goat serum in PBS. Nuclear counterstaining was performed with 1 mg ml À1 of 46-diamidino-2-phenyl indole (DAPI; Roche Diagnostics Corporation), whereas staining with hematoxylin-Gill 2 Â (Fisher Scientific, Springfield, NJ) and Eosin Y (Sigma-Aldrich, St Louis, MO) staining was performed using standard procedures. Reticulin staining was performed on formalin-fixed, paraffin-embedded tumor sections by the Gomori silver impregnation procedure.
Statistical analysis
Analysis of sigmoidal dose-response curves was performed using the program ALLFIT. 25 Tumor progression data were analyzed by repeated-measures analysis of variance (ANOVA), whereas relative luciferase data were analyzed by one-way ANOVA. All post hoc analyses was performed using the Holm-Sidak's test, with a level of Pp0.05 considered statistically significant for all experiments.
Results PDGF-A regulatory elements provide enhanced cytopathogenic responses to GCV in multiple tumor cell lines Plasmids were constructed with the À261 to þ 8 fragment of the PDGF-A promoter (AChP) and the ACE66 enhancer in series with the TK gene from herpes simplex virus-1 ( Figure 1) . TK mediates the first phosphorylation step that is critical for activation of the prodrug GCV. Transient transfection of JEG-3 choriocarcinoma cells with a plasmid containing the AChP (pAdLINKAChPtk) resulted in significant TK expression (Figure 2) , consistent with the high AChP activity and PDGF-A expression observed previously in this cell line. 15 Addition of three tandem copies of the ACE66 element to the AChP (pAdLINK-3XACE/AChPtk) resulted in a fivefold enhancement of TK expression in JEG-3 and HepG2 hepatoma cells, in accord with the ACE66 activity described previously for both lines. 15 In H441 lung adenocarcinoma cells, the AChP provided TK expression but the ACE66 element provided no additional enhance- 26 Only trace TK expression was obtained with a promoterless TK vector.
PDGF-
To assess the ability of the PDGF-A elements to promote GCV-induced cytopathogenicity, a tumor cell line panel was cotransfected with separate plasmids for expression of TK and GFP, the latter to permit enrichment of transfected populations by fluorescence-activated cell sorting. TK expression obtained with the AChP alone conferred significant increases in GCV-induced cytopathogenicity in JEG-3 (10-fold), HepG2 (B70-fold) and U87 MG glioblastoma (B100-fold) cells (Figure 3 ; Table 1 ), but significantly lower potentiation in U2-OS (human osteoblast-like osteosarcoma) cells. The ACE66 trimer provided a further B6-to 7-fold enhancement of GCV potency in JEG-3, HepG2 and U2-OS cells, but had no effect in U87 MG cells. This tumor-type selectivity of the ACE66 enhancer is consistent with previous reporter gene studies, 15 as well as TK expression patterns obtained with these vectors (Figure 2) . In HepG2 cells, the AChP/ACE66 combination provided a greater than 500-fold increase in GCV potency.
To further examine the utility of the AChP and ACE66 enhancer elements for directing gene expression in tumor cells, they were linked in various combinations to known tissue-specific transcriptional control motifs. The promoter from the human glycoprotein hormone a-subunit gene (hGPHaP) was selected for its strong activity in cells of placental trophoblast and choriocarcinoma origin, whereas the human a-fetoprotein promoter (a-fpP) and E1 enhancer from the mouse H19 (H19 E1) were chosen for their activities in hepatoma cell lines. 28, 29 Luciferase reporter plasmids constructed with these elements in various combinations were analyzed by transient transfection in JEG-3 choricarcinoma and HepG2 hepatoma cells. U87 MG cells were included as an example of high AChP/low ACE66 activity, whereas Saos-2 cells represented the transcriptionally inactive condition for both PDGF-A-derived elements.
Plasmids harboring the ACE66 trimer/AChP cassette yielded expected patterns of strong enhancer activity in JEG-3 (151-fold) and HepG2 (15-fold), reduced activity in U87 (sevenfold), and no activity in Saos-2 cells (Table 2) . Also as expected, the hGPHa promoter (hGPHaP) exhibited high activity in JEG-3 cells, 320-fold greater than from the AChP, but much lower levels in U87 and Saos-2 cells. Fusion of the ACE66 trimer and hGPHaP yielded activity in JEG-3 cells (618-fold relative to AChP alone) twofold greater than the hGPHa promoter alone, and fourfold greater than the ACE66 trimer/AChP combination. The ACE66/GPHaP fusion was inactive in U87 and Saos-2 cells. Pairing of the AChP with the liverspecific H19 E1 enhancer provided sixfold enhancement relative to the AChP alone in HepG2 cells, with limited enhancement also observed in U87 (1.8-fold) and Saos-2 (2.8-fold) cells. Fusion of ACE66 and H19 E1 enhancers with the AChP resulted in additive activity relative to the AChP alone (16-fold). Surprisingly high enhancer activity was also observed in U87 (19-fold), but not Saos-2 cells. Highest transcriptional activity in HepG2 cells was obtained with the ACE66 trimer/a-fpP fusion, approximately fivefold higher than a-fpP alone and 99-fold higher than AChP alone. These results indicate potential for exploiting both the tumor cell specificity of PDGF-A elements and the cell type-specific activity of other motifs. Figure S1 ). Thus, further analyses were restricted to the AChP-driven virus, Ad5-AChPtk. Only trace levels of TK expression were obtained with promoterless Ad5 virus containing the TK gene (Ad5-tk; Figure 4) .
Infection with Ad5-AChPtk (AChP alone) conferred a pronounced hypersensitivity to GCV treatment across a panel of human tumor cell lines ( Figure 5 ; Table 3 ), including HepG2, U87 MG and U2-OS and the choriocarcinoma lines JEG-3 and JAR. Enhancement of GCV-induced cytopathogenicity by the Ad5-AChPtk virus ranged between B300-fold in JEG-3 and HepG2 cells to 42000-fold in the U87 MG line. Specificity of Ad5-AChPtk treatment was confirmed by lack of hypersensitization in Saos-2 (osteosarcoma), and the nontransformed cell lines FK121 (keratinocyte) and Hs68 (foreskin fibroblasts), all of which exhibit little or no PDGF-A expression. 30 High viral infection efficiency PDGF-A elements in antineoplastic gene therapy A Mishra et al was verified for these cell lines by parallel studies with a GFP-expressing adenoviral construct (Ad5-CMV/IRES/ gfp; Supplementary Data; Figure S2 ).
Administration of Ad5-AChPtk adenovirus promotes GCV-induced regression of U87 MG xenografts in athymic nude mice In vivo assessment of the Ad5-AChPtk adenovirus was conducted using subcutaneous xenografts of U87 MG cells in athymic nude mice. The U87 MG cell line was selected because of its aggressive growth characteristics in tumor explant form, as well as the robust virus-mediated response observed for these cells in culture. Tumors receiving either saline, an irrelevant control virus (Ad5-CMV/IRESgfp), or Ad5-AChPtk grew aggressively within 14 days to volumes ranging between 300 and 600 mm 3 ( Figures 6 and 7) . In contrast, almost complete regression was observed for tumors receiving Ad5-AChPtk plus GCV treatment. GCV administration had no significant effect on tumors receiving saline or the control Ad5-CMV/IRESgfp virus. Hematoxylin/eosin staining of sections obtained from tumors treated with the Ad5-AChPtk plus GCV combination revealed large areas of cell death (Figure 8a, left) . In addition, DAPI staining Figure 5 Infection with the AChP-containing adenovirus, Ad5-AChPtk, confers potent chemosensitization to ganciclovir (GCV) in tumor cell lines known to overexpress platelet-derived growth factor-A (PDGF-A). Six transformed (JEG-3, JAR, HepG2, U87, U2-OS and Saos-2) and two nontransformed (FK121 and Hs68) cell lines were infected with the adenoviruses Ad5-AChPtk or the negative control Ad5-CMVLacZ. After 16 h, cells were treated with the indicated concentrations of GCV. Cell viability was determined by MTS assay seven days after the GCV treatment.
PDGF-A elements in antineoplastic gene therapy
A Mishra et al revealed a marked increase in the incidence of apoptotic features in the necrotic region of tumors concurrently treated with the therapeutic virus Ad5-AChP-tk and GCV, such as nuclear shrinkage, clumping and superaggregation of chromatin, and the presence of residual bodies (Figure 8b, right) . The same necrotic regions were also strongly positive for TUNEL (Figure 8b ) staining. Positive immunoreactivity for TK was widely distributed across tumors infected with Ad5-AChPtk, both in the presence and absence of GCV administration ( Figure 8c) . As PDGF-A expression has been detected in mesenchymal cell types that would be expected to comprise the activated tumor stroma (for example fibroblasts, endothelial and vascular smooth muscle cells; references [31] [32] [33] ), TK expression and GCV-mediated killing may have been targeted not only to the tumor cell but to stromal cells by the AChP-driven vector. To assess the potential effects of the respective treatments on integrity of the stromal compartment, sections were evaluated by staining for reticular fibers, which provide relevant insights into integrity and vascular content of tumor tissues. Tumors treated with only the therapeutic virus but no GCV displayed prominent blood vessels and multilayered nests of tumor cells surrounded by well-organized reticulin fiber networks (Figure 9 ). In contrast, tumors receiving the Ad5-AChPtk plus GCV treatment combination exhibited reduced vascularization as well as poorly organized reticulin fibers, with cells present for the most PDGF-A elements in antineoplastic gene therapy A Mishra et al part in single layers. These deficits in reticulin networks and vascularization suggest the virus-drug treatment had targeted the tumor stroma directly, although these effects could also have been secondary to effects on the primary tumor cell.
Discussion
The AChP and the ACE66 enhancer induced TK expression at levels sufficient to confer hypersensitization to GCV in multiple tumor cell lines in vitro. A primary focus was placed in this study on cell lines in which ACE66 activity was established previously, such as those of choriocarcinoma (JEG-3, JAR, BeWo), hepatoma (HepG2) and osteosarcoma (U2-OS) origins. Also included were U87 MG glioblastoma cells, which are known to express high levels of PDGF-A via elevated promoter activity, but do not exhibit ACE66 activation. However, many other cancer types also overexpress PDGF-A, such as carcinomas of the breast, [34] [35] [36] prostate, 4 ovary 3 and pancreas, 5,37 as well as melanoma 38, 39 and sarcoma. 40 Thus, the AChP and, in many cases, the ACE66 element, are likely to be hyperactivated and may have applicability to these cancers as well.
A significant outcome of this study was the pronounced GCV-induced cytopathogenicity achieved with the AChP in the context of adenoviral delivery. In a cell culture setting, the virus conferred chemosensitization to GCV ranging between 300-and 2000-fold in four tumor cell lines of diverse origins (choriocarcinoma, hepatoma, osteosarcoma, glioblastoma). Potentiation was restricted to cell lines that are known to overexpress PDGF-A, and was not observed in control lines exhibiting little or no PDGF-A expression. This selectivity suggests therapeutic gene expression directed by the AChP in vivo is restricted to cancer cells. Strong chemosensitization was observed when the AChP-containing virus was applied to tumor explants of the U87 MG glioblastoma cell line in athymic nude mice. Reduction of these aggressively growing tumors to small-to-undetectable sizes by the adenovirus/ GCV treatment strongly suggested a strong bystander effect, as full distribution of the virus was unlikely via the three (B10 ml) intratumoral injections employed. In addition, the adenovirus/GCV treatment inhibited formation of intratumoral blood vessels and the reticulin fiber network, suggesting either direct cytotoxic effects on stromal cell types or indirect effects secondary to targeting of the primary tumor cells themselves. Of note was the lack of overt systemic toxicity to the mice (for example hemorrhaging) over the duration of the treatment, suggesting antistromal effects were selective for the highly activated tumor environment and that normal stromal tissues are probably spared when the AChP is employed. Glioblastoma multiforme may be particularly well-suited to AChP-driven gene therapy in light of our results, and the strong constitutive PDGF expression seen in a large cohort of these patients. [41] [42] [43] In fact, PDGF ligand overexpression is one of the earliest hallmarks of transformation in these tumors, 42 suggesting applicability of the AChP to gene therapy in early stages of the disease.
Inactivation of ACE66 enhancer activity by adenoviral infection indicates that exploitation of its cancer-specific properties will require a different delivery strategy. Adenoviruses are well documented to induce an innate immune response upon interaction with the high-affinity Coxsackie-adenovirus receptor, as well as lower affinity binding to a v integrins (a v a 3 , a v a 5 , a v a 1 ) on target cells (for a review, see Liu and Muruve 44 ). The activated integrin receptor is the source of at least two signaling cascades which activate the mitogen-activated protein kinases extracellular signal-regulated kinase1/2 and p38, which in turn activate the transcription factor nuclear factor-kB and, ultimately, leads to transcription of cytokine genes. In addition, the innate immune response to adenoviral infection is mediated via signaling initiated by cell surface molecules containing Toll-like receptor/ interleukin-1 receptor domains. 45 Inactivation of the ACE66 enhancer by adenoviral infection is counterintuitive, in light of our demonstration that its activity is dependent upon constitutive signaling via the jun-kinase pathway. 18 Although this inhibition of the ACE66 element poses a temporary hurdle for immediate application to cancer gene therapy, the phenomenon does provide insights into inhibitory signaling pathways controlling PDGF-A gene transcription that warrant further investigation. To date, the ACE66 element is most active when delivered in plasmid form, suggesting recent advances in nonviral approaches to gene delivery may be of use. 46 Lentiviral vector delivery was investigated as an alternative to adenovirus, with the premise that genomic integration might permit ACE66 activity once innate immune signaling initiated by infection had subsided. Using GFP as the reporter, we observed that the lentivirus which contained the AChP yielded few cells with low, but detectable GFP expression (2% of total; Supplementary Data; Figure S2 ). When the ACE66 trimer was included, a greater proportion of cells were GFPpositive (22%), but the average GFP expression per cell was not higher than that achieved with the promoter alone. These data indicate optimal functioning of the ACE66 element is sensitive to genomic context, but also suggest some utility in opening regions of transcriptionally silent DNA. Another viral option under investigation in our laboratory is adeno-associated virus, which integrates in a site-specific manner on human chromosome 19. 47 Although the cancer cell specificity of the AChP and ACE66 enhancer elements represents their most significant attribute, our studies indicate this feature can also be combined with the cell type-specific characteristics of other transcriptional elements to achieve even higher levels of gene expression. Of particular interest was the combination of the ACE66 element with the a-fpP, which provided much stronger activity in HepG2 hepatoma cells than that achieved with the a-fpP promoter alone ( Table 3 ). The ACE66 element also provided a significant boost to hGPHa promoter activity in JEG-3 choriocarcinoma cells. Thus, the AChP and ACE66 enhancer may provide useful combinatorial options for achieving an optimal balance of total expression with cancer cell specificity in a given cell type. Overall, these studies provide proof-of-principle that the PDGF-A gene possesses transcriptional control elements that provide significant cancer cell-specific expression. Moreover, they suggest that other genes encoding growth factors and their receptors that are similarly overexpressed in human malignancies may be a rich source of transcriptional control elements applicable to cancer gene therapy.
